World News   USA   California   Bay Area   Business   Bio Tech   San Francisco (44)
San Francisco, Bio Tech Timeline Sunday, November 22 Bookmark and Share     Author
Search Bay Area News Atlas:
Genentech to buy Seragon Pharmaceuticals  Genentech, which is part of Roche, will pay for a San Diego company developing treatments for the most common kind of breast cancer Biotech deal could mean $350 million for Five Prime Therapeutics Genentech invests $285 million in biotech in state New Bay Bridge ready for on-time opening Work moving quickly on new Bay Bridge span
World News (13) World Bio Tech (27) USA (329) California (176) Bay Area (13) Bay Area Bio Tech (137) Business (1641) Bio Tech (137) San Francisco (44)
Avastin (14) Pfizer (5) Herceptin (3) Lucentis (2)
   San Francisco (18)    North San Mateo County (39)    Daly City    SF Downtown (4)    SF City Hall    Giants    South SF (40)    Bay Bridge (3)    Brisbane (10)    Genentech (48)

2014 (3) 2013 (4) 2011 (3) 2010 (5) 2009 (11) 2008 (8) 2007 (1) 2006 (2) 2005 (1) 2004 (3) 2003 (2) 2002 (1)
San Francisco on Wikipedia San Francisco on Web
Hyperion (2)   Roche (16)   Eastern Span Bridge Construction   San Francisco Bridge Construction   Bay Area Construction (190)

Merger and Acquisition Main Event: Work movi...
San Francisco, Bio Tech on Google Map

1. 2015-03-31 Horizon Pharma to buy Brisbane’s Hyperion Therapeutics Brisbane
2. 2014-08-24 Roche buys Brisbane drugmaker InterMune for $8.3 billion Brisbane
3. 2014-07-02 Genentech to buy Seragon Pharmaceuticals Genentech
E. 2014-03-17 Biotech deal could mean $350 million for Five Prime Therapeutics South SF
F. 2013-10-14 Genentech invests $285 million in biotech in state million is heading for state biotech, which will also provide a boost to the drive, Genentech
G. 2013-09-02 New Bay Bridge ready for on-time opening Eastern Span
2013-09-01 Work moving quickly on new Bay Bridge span Eastern Span
8. 2013-08-27 Amgen to Buy Onyx for $10.4 Billion to Gain Cancer Drug South SF
J. 2011-12-28 Solazyme CEO resigns South SF

Roche buys Brisbane drugmaker InterMune for $8.3 billion
Horizon Pharma to buy Brisbane’s Hyperion Therapeutics

March 2015 ... more > Top ^
Mar.31   Brisbane
  Horizon Pharma agreed to buy Brisbane’s Hyperion Therapeutics for $1.1 billion to gain drugs to treat rare metabolic diseases

year 2014 Top ^

Aug.24   Brisbane
  Swiss pharmaceutical giant is expanding its respiratory disease treatments by acquiring InterMune at $74 per share in an all-cash transaction
Jul.2   Genentech
Mar.17   South SF

year 2013 Top ^

Oct.14   Genentech
Sep.2   Eastern Span
Sep.1   Eastern Span
  Round-the-clock work to open the new eastern span is proceeding smoothly and transportation officials are putting the finishing touches on a ceremony
Aug.27   South SF Amgen to Buy Onyx for $10.4 Billion to Gain Cancer Drug  Amgen Inc. agreed to buy Onyx Pharmaceuticals Inc. in a $10.4 billion to give Amgen access to a rapidly expanding cancer-drug market

year 2011 Top ^

Dec.28   South SF Solazyme CEO resigns May.27   South SF Solazyme's solid IPO  Startup that makes algae-based biofuel, raised nearly $200 million; the stock finished on the Nasdaq at $20.71 with a 15% gain Apr.27   Brisbane Stock of InterMune soaring

year 2010 Top ^

Dec.2   SF City Hall S.F. approves biodiesel plant
Jul.20   Genentech Panel doesn't back Avastin for cancer Jul.2   Genentech Avastin delays ovarian cancer May.17   San Francisco Bayer, Nektar moving into Mission Bay Jan.9   Genentech FDA Approves Actemra Arthritis Drug

year 2009 Top ^

Oct.27   San Francisco Medivation to develop cancer drug
Oct.3   San Francisco Taker found for Mission Bay office space   A growing South Bay biotech company Nektar Therapeutics Inc. will take over office space recently abandoned by drug giant Pfizer Aug.2   Genentech FDA clears drug for kidney cancer  Food and Drug Administration approved its cancer treatment Avastin for a new use, marking the sixth approval for the blockbuster drug Jul.9   Genentech Axe falls at Genentech  Anxiety rippled through Genentech as Roche began to cut rank-and-file jobs as it folds the South SF biotech firm into its global operations Jul.6   San Francisco Pfizer drops planned research center  New York drug giant has pulled the plug on plans to open a biotech research center near UCSF's Mission Bay Campus Apr.8   Genentech Drug Raptiva pulled from market  The unit of drugmaker Roch is pulling the psoriasis treatment Raptiva off the U.S. market because of links to an often fatal brain infection Mar.12   Genentech Roche to take over Genentech for $47B
  Swiss giant agreed to buy the 44% of biotech pioneer that it doesn't already own, ending a long corporate struggle
 The $95-per-share deal brings Roche all of the sales of cancer drugs as well as its promising research pipeline. The deal offers $95 per share for the 44 percent of Genentech that Roche Holding AG doesn't already own
Mar.9   Genentech Roche-Genentech deal called close  Roche is reportedly willing to pay Genentech $95 a share, up from the $93, in what would be a $46.7 billion deal Mar.6   Genentech Roche raises bid for Genentech  Swiss drugmaker increased its offer to $93 per share. Genentech shares shot up to $90.05, gaining $8.41 or 10 percent Feb.9   Genentech Roche launches $86.50-a-share bid  Swiss drugmaker officially launched its $42 billion hostile offer for the 44% of Genentech Inc. it doesn't already own Jan.30   Genentech Roche revives takeover bid of Genentech  Swiss drugmaker, frustrated by stalled negotiations, plans a hostile takeover at a lower price than the $89 per share rejected in August

year 2008 Top ^

Nov.18   Genentech Avastin linked to higher risk of clots Aug.27   South SF Cell Genesys Drug Trial Halts Aug.13   Genentech Genentech rejects Roche's $43.7b bid Aug.6   San Francisco Pfizer moving biotech research unit to S.F.
  The world's largest drugmaker will move the headquarters of its new biotech research unit to Mission Bay, next door to UCSF's new campus
Jul.21   Genentech Roche Offers $44B For Remaining Shares Apr.30   Genentech Bad news on cancer drug Rituxan Apr.24   Genentech Court slashes $200 million from judgment Feb.22   Genentech FDA Clears Avastin for Breast Cancer
  A Genentech drug received federal approval, a surprise decision

year 2007 Top ^

Dec.5   Genentech FDA Panel Rejects Avastin, stock drops

year 2006 Top ^

Jul.31   Genentech Tony Blair Visits Genentech Headquarters
Feb.13   Genentech Cancer Drug Trials Scaled Back

year 2005 Top ^

Jul.11   Genentech Profits Soar 73% in 2Q

year 2004 Top ^

Nov.4   Brisbane VaxGen gets contract for anthrax vaccine
  The government is purchasing 75 million doses of a new generation vaccine under an $877.5 million Jun.8   SF Downtown 150 protesters held at biotech conference
  About 200 demonstrators failed to shut down the annual Biotechnology Industry Organization convention Jun.6   SF Downtown Biotech conference opens  18,000 biotechnology scientists, executives and government officials were welcomed with a mayor and jeering protesters

year 2003 Top ^

May.19   Genentech Encouraging results with cancer drug
  Avastin extended the lives of some of the colon cancer patients. Company's stock soaring nearly 45% Feb.23   Brisbane AIDS vaccine developed by VaxGen
  An experimental vaccine does not protect most people, but showed promise in protecting blacks and Asians

year 2002 Top ^

Sep.7   Genentech Big patent win vs. Chiron

Add a favorite (file a bookmark) to San Francisco, Bio Tech Timeline

Please send feedback to:

Advertise on San Francisco, Bio Tech Page

To sell or purchase a home in the San Francisco complete this form